Adalimumab added to methotrexate yields better results in PsA than methotrexate escalation

Results from the phase 4 CONTROL trial shows that adding adalimumab to the treatment regimen of methotrexate results in better outcomes than methotrexate dose escalation in patients with psoriatic arthritis who did not respond sufficiently to initial methotrexate therapy.

Results from the ongoing phase 4 CONTROL trial shows that adding adalimumab to the treatment regimen of methotrexate results in better outcomes than methotrexate dose escalation in patients with psoriatic arthritis (PsA) who did not respond sufficiently to initial methotrexate therapy [1].

The study, presented by Dr Laura Coates (Oxford University, United Kingdom), enrolled 245 biologic-naïve patients with active psoriatic arthritis despite treatment with methotrexate for at least 4 weeks. Patients were randomised to add-on adalimumab 40 mg every 2 weeks (n=123) or methotrexate dose escalation to a maximum of 20-25 mg/week (n=122; the average dose of methotrexate was 21.8 mg/week).

At week 16, the results showed that 41.5% of patients who were treated with adalimumab achieved minimal disease activity (MDA) compared with 13.1% MDA of patients who received methotrexate escalation treatment. The significantly higher rates of MDA in the adalimumab group occurred irrespective of prior methotrexate treatment duration; rates were 42.2% versus 9.8% for patients treated for up to 3 months and 40.7% versus 16.4% for those treated for a longer period of time. Significant differences in MDA rates between the 2 groups were seen after 4 weeks of treatment. The between-group difference increased with time over the 16-week study period. The ACR20, ACR50, and ACR70 response rates also showed the superiority of adalimumab, and significantly higher PASI75, PASI90, and PASI100 response rates were seen in adalimumab-treated patients who suffered from significant psoriasis.

The occurrence of adverse events of any grade was similar in both treatment groups from baseline to week 16 (61.8 vs 57.4% for adalimumab and methotrexate dose escalation group, respectively). There were no reports of any opportunistic infections, deaths, or tuberculosis or malignancy. The study is currently ongoing and is evaluating whether treatment modification with adalimumab or methotrexate impacts on the achievement and maintenance of MDA.

Source:
1. Coates LC, et al. Adalimumab Introduction Versus Methotrexate Dose Escalation in Patients with Inadequately Controlled Psoriatic Arthritis: Results from Randomized Phase 4 CONTROL Study. Abstract OP0050. EULAR E-Congress, 3-6 June 2020.

Esanum is an online network for approved doctors

Esanum is the medical platform on the Internet. Here, doctors have the opportunity to get in touch with a multitude of colleagues and to share interdisciplinary experiences. Discussions include both cases and observations from practice, as well as news and developments from everyday medical practice.

Esanum ist ein Online-Netzwerk für approbierte Ärzte

Esanum ist die Ärzteplattform im Internet. Hier haben Ärzte die Möglichkeit, mit einer Vielzahl von Kollegen in Kontakt zu treten und interdisziplinär Erfahrungen auszutauschen. Diskussionen umfassen sowohl Fälle und Beobachtungen aus der Praxis, als auch Neuigkeiten und Entwicklungen aus dem medizinischen Alltag.

Esanum est un réseau en ligne pour les médecins agréés

Esanum est un réseau social pour les médecins. Rejoignez la communauté et partagez votre expérience avec vos confrères. Actualités santé, comptes-rendus d'études scientifiques et congrès médicaux : retrouvez toute l'actualité de votre spécialité médicale sur esanum.